Literature DB >> 3623018

Aminopyrine N-demethylation by rats with liver cirrhosis. Evidence for the intact cell hypothesis. A morphometric-functional study.

J Reichen, B Arts, U Schafroth, A Zimmermann, B Zeltner, T Zysset.   

Abstract

The intact cell hypothesis states that a reduced number of intrinsically normal hepatocytes, together with hemodynamic alterations, explains decreased drug metabolism in cirrhosis. We explored this hypothesis by comparing results of the aminopyrine breath test with in vitro measurements of aminopyrine N-demethylation and morphometrically determined liver cell volume in a rat model of cirrhosis. Aminopyrine N-demethylation in vivo (ABT-k) was 0.98 +/- 0.10/h (mean +/- SD) in controls. The cirrhotic rats were separated into those with normal (NCR) and those with abnormal ABT-k (PCR). Microsomal aminopyrine N-demethylase averaged 2.08 +/- 0.77 and 2.09 +/- 0.54 mumol/min in controls and NCRs, respectively; it was reduced to 1.00 +/- 0.81 mumol/min (p less than 0.02) in PCRs. Morphometrically determined hepatocellular volume was 18.8 +/- 2.8, 17.1 +/- 1.9, and 11.6 +/- 6.1 ml in controls, NCRs, and PCRs, respectively, PCRs being lower than controls (p less than 0.01) and NCRs (p less than 0.05). When N-demethylase and cytochrome P450 were related to hepatocellular volume (in milliliters), no significant difference between the three groups was apparent. We conclude that reduced aminopyrine N-demethylation in progressed cirrhosis is mainly due to a loss of liver cell volume. The function per liver cell volume remains constant, however, thus favoring the intact cell hypothesis for the handling of slowly metabolized compounds such as aminopyrine.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3623018     DOI: 10.1016/0016-5085(87)90433-1

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  7 in total

Review 1.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

2.  Determinants of hepatic function in liver cirrhosis in the rat. Multivariate analysis.

Authors:  J Reichen; B Egger; N Ohara; T B Zeltner; T Zysset; A Zimmermann
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

3.  Hepatosplanchnic haemodynamics and renal blood flow and function in rats with liver failure.

Authors:  P Javlé; J Yates; H G Kynaston; K F Parsons; S A Jenkins
Journal:  Gut       Date:  1998-08       Impact factor: 23.059

4.  Abnormal lipid composition of microsomes from cirrhotic rat liver--does it contribute to decreased microsomal function?

Authors:  J Reichen; J T Buters; Z Sojcic; F J Roos
Journal:  Experientia       Date:  1992-05-15

5.  Action of methotrexate on cytochrome P-450 monooxygenases in rats. Study performed with [13C]-aminopyrine micro breath test.

Authors:  J Guitton; G Souillet; J L Rivière; F Gerard; R Guilluy; J L Brazier
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Apr-Jun       Impact factor: 2.441

Review 6.  Hepatic circulation: potential for therapeutic intervention.

Authors:  F Ballet
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

7.  Low NO bioavailability in CCl4 cirrhotic rat livers might result from low NO synthesis combined with decreased superoxide dismutase activity allowing superoxide-mediated NO breakdown: A comparison of two portal hypertensive rat models with healthy controls.

Authors:  Marc Van De Casteele; Jos F Van Pelt; Frederik Nevens; Johan Fevery; Jürg Reichen
Journal:  Comp Hepatol       Date:  2003-01-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.